Pages that link to "Q33543832"

The following pages link to Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer (Q33543832):

Displaying 28 items.

• The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients (Q26782449) (← links)
• Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis (Q27853296) (← links)
• Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells (Q34259906) (← links)
• The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers (Q34861658) (← links)
• NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms. (Q35469769) (← links)
• A role for estrogen receptor phosphorylation in the resistance to tamoxifen (Q35684445) (← links)
• Immune microenvironment as a factor of breast cancer progression. (Q35780464) (← links)
• PRC2 regulates RNA polymerase III transcribed non-translated RNA gene transcription through EZH2 and SUZ12 interaction with TFIIIC complex (Q35885921) (← links)
• An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients (Q35927942) (← links)
• High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer (Q36070061) (← links)
• Significance of EZH2 expression in canine mammary tumors (Q36098022) (← links)
• Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions (Q36292201) (← links)
• Derailed estrogen signaling and breast cancer: an authentic couple. (Q36589361) (← links)
• The interaction between ER and NFκB in resistance to endocrine therapy. (Q36924406) (← links)
• Oestrogen receptor negativity in breast cancer: a cause or consequence? (Q37529397) (← links)
• Epigenetics of Estrogen Receptor Signaling: Role in Hormonal Cancer Progression and Therapy (Q37911312) (← links)
• EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis (Q38019814) (← links)
• Update of research on the role of EZH2 in cancer progression (Q38099319) (← links)
• Targeting the NFκB signaling pathways for breast cancer prevention and therapy. (Q38267049) (← links)
• Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies? (Q38975402) (← links)
• SUPT6H controls estrogen receptor activity and cellular differentiation by multiple epigenomic mechanisms. (Q39033038) (← links)
• Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer (Q39491238) (← links)
• A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer (Q46799300) (← links)
• Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. (Q53125766) (← links)
• Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome (Q53237147) (← links)
• Cyclin-dependent kinase 1-mediated AMPK phosphorylation regulates chromosome alignment and mitotic progression (Q90100220) (← links)
• Examination of Hypoxanthine Guanine Phosphoribosyltransferase as a biomarker for colorectal cancer patients (Q91711019) (← links)
• Falling from grace: HPRT is not suitable as an endogenous control for cancer-related studies (Q92309020) (← links)